The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases. The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases. The present invention relates to compounds of general formula I, wherein the groups R1, R2, L1, L2, U and B are as defined in the application, which have valuable pharmacological properties, and in particular modulate the activity of the MCH receptor.La presente invención se refiere a composiciones farmacéuticas que comprenden combinaciones de dosis fijas de un fármaco inhibidor de DPP-4 y/o un fármaco inhibidor de SGLT-2, y metformina XR, procesos para su preparación, y su uso para tratar ciertas enfermedades.
